Emerging Markets Are Next Turn In Sanofi Consumer Health Growth
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Sanofi's consumer health sales were off 1%, at $1.4bn, during its latest quarter compared to a corresponding year-ago period, with inclusion of Boehringer's OTC drug and nutritional product brand revenues. But for Sanofi's legacy consumer products only, sales were up 42.5%.
You may also be interested in...
Sanofi's Consumer Business Starts 2017 With 'Reassuring' Momentum
Sanofi consumer products head Alan Main says BI's brands will "lift Sanofi into leadership positions in attractive OTC categories, namely the vitamins and minerals supplements market, digestive products, cough and cold as well as pain medications."
Sanofi Adds Consumer Brands, Grows Footprint With Boehringer Ingelheim Deal
BI international brands including Mucoangin cough suppressant and Dulcolax constipation treatment and US heartburn remedy Zantac would join Sanofi's consumer portfolio including US brands Allegra Allergy antihistamines and Nasacort Allergy 24HR nasal decongestant in the firm's proposed asset swap.
Mandatory Product Listing: Needed For US VMS Market, Not Mandatory In User Fee Bill – CRN
Establishing VMS products MPL as stated within legislation to re-authorize FDA user fee programs for drugs, biologics and medical device applications isn’t urgent enough to prevent passing user fee bill, says CRN chief Steve Mister.